Zai Lab Limited Unsponsored ADR
ZLAB Healthcare Biotechnology
Zai Lab Limited Unsponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $460.2 million, up 15.3% from fiscal 2024. In the quarter to June 2026, revenue fell 3.33%, EPS fell 24.3%, free cash flow fell 84.4% and total debt rose 36.4%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
Follow ZLAB
Zai Lab Limited Unsponsored ADR (ZLAB) EV/Sales
As of 16 October 2026, Zai Lab Limited Unsponsored ADR (ZLAB) trades at a EV/Sales of 4.7×. Over the past ten years it has ranged from 0.0× (December 2019) to 422× (February 2020); the current reading is higher than 41% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.9× | (36.64%) |
| FY2024 | 4.6× | (28.30%) |
| FY2023 | 6.4× | (29.05%) |
| FY2022 | 9.1× | (70.49%) |
| FY2021 | 30.8× | (81.13%) |
| FY2020 | 163× | (40.04%) |
| FY2019 | 272× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.7× | 7.86% |
| Mar 2026 | 3.4× | 15.71% |
| Dec 2025 | 2.9× | (58.57%) |
| Sep 2025 | 7.1× | (4.35%) |
| 26 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MBX MBX Biosciences, Inc. compare | n/m |
| DYN Dyne Therapeutics, Inc. compare | n/m |
| ELVN Enliven Therapeutics, Inc. compare | n/m |
| NRIX Nurix Therapeutics, Inc. compare | 2.4× |
| ZLAB Zai Lab Limited Unsponsored ADR | 4.7× |
| BEAM Beam Therapeutics Inc. compare | 8.9× |
| RCUS Arcus Biosciences, Inc. compare | 18.7× |
| PGEN Precigen, Inc. compare | 27.2× |
| NAMS NewAmsterdam Pharma Company N.V. compare | 254× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)